TEVA-PHARMACEUTICAL
8.4.2021 09:02:08 CEST | Business Wire | Press release
Teva Pharmaceuticals Europe announced that it has received EU Marketing Authorisation for Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) as a maintenance treatment for asthma in adults and adolescents aged 12 years and older. Initial launches are planned in Portugal, Switzerland, Spain and the UK.
Introducing Seffalair Spiromax and BroPair Spiromax
The launch of Seffalair Spiromax and BroPair Spiromax further extends Teva’s respiratory portfolio, and provides healthcare professionals another option in treating people living with asthma. Since the launch of DuoResp® Spiromax® (budesonide/formoterol), the Spiromax® inhaler has been well received by healthcare professionals and patients.1,2
Inhaler technique and treatment adherence are key factors in improving outcomes for asthma patients, of which there are an estimated 28 million in the EU.3,4
"We are excited about the European approval of Seffalair Spiromax and BroPair Spiromax, as an important goal of our respiratory franchise is to bring new treatment options to healthcare professionals who support people living with long-term conditions such as asthma,” says Paul Blonk, Head of Teva Respiratory Europe. “We want to empower patients to effectively manage their condition through the medicines we provide, whilst also offering cost-effective treatments to healthcare systems.”
About Seffalair Spiromax and BroPair Spiromax (salmeterol xinafoate / fluticasone propionate)
Seffalair Spiromax and BroPair Spiromax are indicated as a regular treatment for asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 agonists.
About Teva Respiratory
Teva Respiratory develops and delivers high-quality treatment options for respiratory conditions, including asthma, COPD and cystic fibrosis. The Teva Respiratory portfolio is centred on optimizing respiratory treatment for patients and healthcare providers through the development of novel delivery systems and therapies that help address unmet needs. Teva’s respiratory pipeline and clinical trial program are based on drug molecules delivered in proprietary dry powder formulations and breath-actuated device technologies, as well as a targeted biologic treatment for severe asthma. Through research and clinical development, Teva Respiratory continually works to expand, strengthen and build upon its treatment portfolio to positively impact the lives of the millions of patients living with respiratory disease.
About Teva
Teva Pharmaceuticals Europe makes life-saving and life-improving medicines more accessible for millions of people around the world. We focus on treatments for migraine, conditions of the central nervous system including pain, as well as respiratory conditions like asthma and COPD and have a portfolio in oncology. Our mission is to be a global leader in generics and biopharmaceuticals improving the lives of patients around the globe.
Building on more than a century-old legacy we have an established presence in generics, specialty, over-the-counter (OTC) and active pharmaceutical ingredients (API). With a fully integrated R&D function, strong operational base and global infrastructure and scale we invest millions of dollars to help our scientists find the next breakthrough.
We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 40,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com .
References
- van der Palen et al. Poster presented at the ERS International Congress, Paris, France, September 2018 (PA1020).
- Roche N, et al. J Asthma, 2021; DOI: 10.1080/02770903.2021.1875482
- GBD. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018. 392 (10159):1789-858.
- Eurostat. First population estimates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005322/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Forrester Opens Nominations For Its 2026 B2B Awards In EMEA17.6.2026 10:42:00 CEST | Press release
Awards recognise organisations for delivering measurable impact through cross-functional alignment Forrester (Nasdaq: FORR) today opened nominations for its 2026 B2B Return On Integration Honours and B2B Programmes Of The Year Awards for Europe, the Middle East, and Africa (EMEA). The awards recognize organisations that are driving measurable business impact through customer-obsessed growth strategies. Winners will be honoured at Forrester’s B2B Forum EMEA, taking place in London, 28–29 September 2026. The B2B Return On Integration (ROI) Honours celebrate organisations that have successfully aligned marketing, revenue, product, and customer functions to deliver measurable outcomes and drive enterprisewide performance. The B2B Programmes Of The Year (POY) Awards recognise standout functional initiatives across areas including marketing, revenue, customer engagement, and product that demonstrate innovation and measurable results. “Today’s B2B leaders are under pressure to deliver growth
Klarna Partners With Bolt to Grow ‘Pay in Full’ for Rides and Scooters17.6.2026 10:20:00 CEST | Press release
Klarna, the global digital bank and payments provider, has partnered with Bolt, the European shared mobility platform, to bring Klarna's payment options directly into the Bolt app. Across Sweden, Germany, Finland and Norway, users can now pay for car rides and scooters with Klarna, with car rentals also available in Germany. The integration is built on tokenised payments, allowing users to pay through their stored credentials without re-entering details for each trip. In all four markets, customers can choose to pay in full or pay monthly with Klarna. The rollout is already underway, with full availability across all four markets expected by the end of June 2026. The partnership brings together two of Europe's largest consumer platforms: Bolt serves more than 200 million customers across over 50 countries, while Klarna has over 119 million active users worldwide. For Klarna, it deepens a growing presence in everyday, high-frequency spending, placing the company at the point of payment
Ohmium and Hynfra Sign Master Cooperation Agreement to Advance Large-Scale Green Hydrogen Projects in the Middle East and Africa17.6.2026 10:17:00 CEST | Press release
Ohmium International Inc., a leading manufacturer of high-efficiency, modular Proton Exchange Membrane (PEM) electrolyzers, and Hynfra P.S.A., a prominent green hydrogen and green ammonia project developer, today announced the signing of a master cooperation agreement to advance green hydrogen projects in Mauritania, Jordan, and Oman. The cooperation agreement covers the projects’ Front-End Engineering and Design (FEED) stage and establishes the framework for ongoing collaboration. Ohmium also will provide technical support and PEM electrolyzer expertise throughout the FEED and development stages for the three hydrogen projects mentioned. These projects are designed to produce green hydrogen for green ammonia applications, advancing energy security and long-term resilience in host countries by building domestically sourced clean energy capacity and reducing dependence on imported fossil fuels, while also supplying RFNBO-compliant green ammonia for export, including to European markets.
ID UNLIMITED Strengthens European Platform With Acquisition of Denmark’s Jet Sport17.6.2026 10:00:00 CEST | Press release
ID UNLIMITED, a European leader in premium equipment personalisation and embellishment services for sports clubs, leagues and global sports brands, has signed an agreement to acquire Jetsport A/S (“Jet Sport”), a provider of personalisation and customisation services headquartered in Viborg, Denmark, specialised in sportswear and workwear. Jet Sport marks the first acquisition under ID UNLIMITED's international expansion strategy since partnering with TowerBrook Capital Partners in April this year. The transaction is expected to close by the end of June 2026, subject to customary conditions. Founded in 1971, Jet Sport is a family-owned business with over five decades of experience in textile embellishment. The company serves sports clubs, sporting goods retailers, workwear suppliers and industrial clients, providing high-quality screen prints, heat transfers and embroideries with approximately 140 employees. Jet Sport has built a reputation for quality, fast turnaround and technical in
Reply Achieves the AWS Business Value Realization Competency17.6.2026 10:00:00 CEST | Press release
Reply [EXM, STAR: REY] announced today that it has achieved the Amazon Web Services (AWS) Business Value Realization Competency. This specialization recognizes Reply as an AWS Partner that helps customers deliver measurable, post-sales business outcomes from their AWS investments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617874809/en/ Reply achieves the Amazon Web Services (AWS) Business Value Realization Competency that recognizes an AWS Partner that helps customers deliver measurable, post-sales business outcomes from their AWS investments. Achieving the AWS Business Value Realization Competency differentiates Reply as an AWS Partner that excels at helping customers define, measure, and achieve business outcomes from their cloud and AI investments. It signals to customers that a Partner has the commitment, trained and certified teams, and a proven track record of delivering measurable outcomes, not just technical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom